Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.
Stevanato Group SpASTVN -0.39%87 5-Year Share Buyback Ratio is 1.10 as of Jun. 2026. GuruFocus rates STVN with a GF Score™ of 87/100 and a GF Value™ of $26.04 (Modestly Undervalued). The stock has 6 warning signs investors should review. Among 636 Medical Devices & Instruments companies, Stevanato Group SpA ranks better than 94.65% on this metric.
Shares Outstanding (EOP) are shares that have been authorized, issued, and purchased by investors and are held by them.
5-Year Share Buyback Ratio measures the average annual proportion of a company's outstanding shares repurchased over the past five years. It is calculated as the annualized percentage change in shares outstanding from five years ago to the current year. A positive ratio may indicate share buybacks over the period, while a zero or negative ratio may reflect no repurchases or potential share issuance. Stevanato Group SpA's current 5-Year Share Buyback Ratio was 1.10%.
STVN's 5-Year Share Buyback Ratio is ranked better than 94.65% of 636
companies
in the Medical Devices & Instruments industry
Industry Median: -3.35
vs STVN: 1.10
Stevanato Group SpA (NYSE:STVN) 5-Year Share Buyback Ratio Explanation
A negative number means the company might be issuing new shares. A positive number indicates that the company is buying back shares.
Be Aware
Investors usually like share buybacks. But as pointed by Warren Buffett, only if a company buys back shares at the prices below the stock's intrinsic value, it rewards remaining shareholders. If a company buys its overvalued stocks back, it destroys shareholder value.
Stevanato Group SpA 5-Year Share Buyback Ratio Related Terms
STVN vs MMED, TFX, MMSI: 5-Year Share Buyback Ratio Comparison
For the Medical Instruments & Supplies subindustry, Stevanato Group SpA's 5-Year Share Buyback Ratio, along with its competitors' market caps and 5-Year Share Buyback Ratio data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
Stevanato Group SpA 5-Year Share Buyback Ratio vs Medical Devices & Instruments Industry
For the Medical Devices & Instruments industry and Healthcare sector, Stevanato Group SpA's 5-Year Share Buyback Ratio distribution charts can be found below:
* The bar in red indicates where Stevanato Group SpA's 5-Year Share Buyback Ratio falls into.
Stevanato Group SpA 5-Year Share Buyback Ratio Calculation
This is the annualized percentage change in shares outstanding from five years ago to the current year. The annualized percentage change is calculated with least-square regression based on the latest six years of annual data on Shares Outstanding (EOP).
Please click Growth Rate Calculation Example (GuruFocus) to see how GuruFocus calculates Wal-Mart Stores Inc (WMT)'s revenue growth rate. You can apply the same method to get the average dividends per share growth rate.
What does a 5-Year Share Buyback Ratio of 1.10 mean?
Stevanato Group SpA (STVN) has a 5-Year Share Buyback Ratio of 1.10 as of Jun. 2026. The 5-Year Share Buyback Ratio measures the average annual proportion of a company's outstanding shares repurchased over the past five years. It is calculated as the annualized percentage change in shares outstanding from five years ago to the current year. View historical data for Stevanato Group SpA and its competitors. According to the industry distribution chart, Stevanato Group SpA ranks #34 out of 636 companies in the Medical Devices & Instruments industry, placing it in the top 5.3%.
Is Stevanato Group SpA's 5-Year Share Buyback Ratio too high?
Stevanato Group SpA's current 5-Year Share Buyback Ratio is 1.10. Based on the distribution chart, Stevanato Group SpA ranks #34 out of 636 companies in the Medical Devices & Instruments industry, which is in the top quartile — a strong position relative to peers. Overall, Stevanato Group SpA has a GF Score™ of 87/100 and is considered Modestly Undervalued, reflecting its overall financial health beyond just this single metric.
How does Stevanato Group SpA's 5-Year Share Buyback Ratio compare to MMED and TFX?
According to the Medical Devices & Instruments industry distribution chart, Stevanato Group SpA ranks #34 out of 636 companies for 5-Year Share Buyback Ratio. This places Stevanato Group SpA in the top 5% of its industry — outperforming the majority of peers. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good 5-Year Share Buyback Ratio for a Medical Devices & Instruments company?
A good 5-Year Share Buyback Ratio depends on the Medical Devices & Instruments industry context. However, 5-Year Share Buyback Ratio should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high 5-Year Share Buyback Ratio mean?
A high 5-Year Share Buyback Ratio can signal that a stock is expensive relative to its fundamentals. The 5-Year Share Buyback Ratio measures the average annual proportion of a company's outstanding shares repurchased over the past five years. It is calculated as the annualized percentage change in shares outstanding from five years ago to the current year. View historical data for Stevanato Group SpA and its competitors. Stevanato Group SpA's current 5-Year Share Buyback Ratio is 1.10. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Stevanato Group SpA stock overvalued right now?
Based on GuruFocus' analysis, Stevanato Group SpA (STVN) is currently considered Modestly Undervalued. The stock's GF Value™ is $26.04, compared to a current price of $20.24 — trading 22.3% below its estimated fair value. The current 5-Year Share Buyback Ratio is 1.10. Stevanato Group SpA's overall GF Score™ is 87/100 with 6 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is 5-Year Share Buyback Ratio calculated?
5-Year Share Buyback Ratio is calculated from a company's financial statements. For Stevanato Group SpA (STVN), the current 5-Year Share Buyback Ratio is 1.10 as of Jun. 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Is Stevanato Group SpA (STVN) Overvalued in 2026?
Based on GuruFocus' analysis, Stevanato Group SpA stock appears to be undervalued.
The current stock price of $20.24 is trading 22.3% below its estimated GF Value™ of $26.04.
GuruFocus considers Stevanato Group SpA to be Modestly Undervalued.
Key valuation signals for STVN:
5-Year Share Buyback Ratio: 1.10
GF Value™: $26.04 vs. price of $20.24 (22.3% below fair value)
No single metric tells the full story. See the STVN stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.
Stevanato Group SpA is a provider of drug containment, drug delivery and diagnostic solutions to the pharmaceutical, biotechnology and life sciences industries. It delivers an integrated, end-to-end portfolio of products, processes, and services that address customer needs across the entire drug life cycle including development, clinical, and commercial stages. It has two segments; Biopharmaceutical and Diagnostic Solutions which generates key revenue, includes all the products, processes and services developed and provided for the containment and delivery of pharmaceutical and biotechnology drugs and reagents, as well as the production of diagnostic consumables and its other segment is Engineering. Geographically, It derives its majority revenue from Europe, Middle East and Africa.
87GF Score
Get the complete analysis for STVN
5-Year Share Buyback Ratio is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
STVN has been successfully added to your 
